Fletcher Building trades at $2.84 vs fair value $5.56, offering 96% upside through construction cycle recovery and strategic portfolio optimization.
View noteNova Eye Medical: BUY rating, A$0.48 fair value vs A$0.14 current price (243% upside). Pre-profit MIGS specialist targeting H1FY26 breakeven with 25% revenue growth.
View noteHOLD rating with fair value $0.133 vs current $0.150. Market leader in ANZ adventure tourism with 25% share, EBITDA margins at 14.7%, facing climate and competitive headwinds.
View noteFair value $0.84 vs current $0.72. 22% EBITDA margins, 72% government funding, 13% revenue growth. Consolidation platform in fragmented market.
View noteHOLD rating with $28.34 fair value vs $27.04 current price. Market leader in independent trustee services with 8.3% FCF yield, though regulatory overhang and fee compression limit upside.
View noteSTRONG SELL rating with 84% downside to $2.20 fair value. EBITDA margins compressing from 26.4% peak as competition intensifies.
View noteQuality gold producer with US$1,075/oz AISC trading at A$4.11 vs A$2.71 fair value. Strong operations, excessive valuation, 34% overvalued.
View notePayment processor trading at 42% discount to peers. Fair value $1.60 vs current $1.07. EBITDA margins recovering from 16.5% toward 26% through transformation programme.
View noteBUY rating with $1.83 fair value vs $0.93 current price. 38.3% EBITDA margins, 18.5% market share, trading at 63% discount to peers despite superior metrics.
View noteHOLD rating with $0.56 fair value vs $0.57 current price. Market leader in seniors' rental (18% share, 98% occupancy) executing risky all-age expansion. 35% execution failure probability creates binary outcomes.
View noteMarket leader trading at 48% discount to peers despite regulatory moats. Fair value $5.02 vs current $4.18 with 20% upside potential.
View noteFair value $0.65 vs current $0.515. 30% EBITDA margins, 46% ROIC, but 89% international student dependency creates binary regulatory risk.
View note